CEO
Robert Brown
Employees
9
Industry
Biological Product (except Diagnostic) Manufacturing
brickell biotech, inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. our management team and board of directors has extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. our strategy is to leverage this experience to in-license, acquire, develop and commercialize products that we believe can be successful in the global dermatology marketplace. our portfolio of five product candidates, all new molecular entities with relevant mechanism of actions in skin diseases, targets significant market opportunities.
Loading...
Open
0.74
Mkt cap
4.4M
Volume
2
High
0.74
P/E Ratio
-0.70
52-wk high
1.03
Low
0.74
Div yield
N/A
52-wk low
0.55
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 1:51 pm
Portfolio Pulse from Benzinga Newsdesk
October 13, 2023 | 8:11 pm
Portfolio Pulse from Lisa Levin
September 20, 2023 | 6:33 pm
Portfolio Pulse from Lisa Levin
September 20, 2023 | 6:10 pm
Portfolio Pulse from Benzinga Insights
September 20, 2023 | 5:31 pm
Portfolio Pulse from Lisa Levin
September 20, 2023 | 2:22 pm
Portfolio Pulse from Benzinga Insights
September 20, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 20, 2023 | 12:58 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.